Coya Therapeutics, Inc. (COYA)

Current Report Filed: 2026-05-12

FDA granted Fast Track Designation to COYA 302 for ALS treatment on May 11, 2026, which accelerates the development and review timeline and signals regulatory confidence in the therapeutic approach.
Q1 2026 financial results were disclosed via press release, though specific financial metrics are not detailed in the 8-K filing itself, limiting ability to assess operational performance.
Coya Therapeutics maintains emerging growth company status, allowing for reduced disclosure and compliance requirements that may provide flexibility but also limit transparency for investors.

Quarterly Report Filed: 2026-05-12

Coya Therapeutics completed a January 2026 private placement offering, indicating ongoing capital raises to fund clinical development and operations, which is typical for pre-revenue or early-stage biotech companies.
The company maintains multiple development agreements including DRL Development Agreement and Patent/Know-How License Agreements, suggesting active collaboration on drug candidate development across different therapeutic areas.
The filing shows significant R&D and G&A expense tracking across Q1 2026, with detailed segmentation of internal R&D costs and stock-based compensation, reflecting the capital-intensive nature of clinical-stage biopharmaceutical development.
Substantial warrant and convertible debt instruments are outstanding from multiple private placements and offerings, which could create significant dilution to existing shareholders upon conversion or exercise.

Current Report Filed: 2026-05-12

Coya Therapeutics established a $30 million at-the-market (ATM) equity offering with Leerink Partners, providing flexible capital access without immediate dilution obligations, suggesting the company is preserving cash while maintaining fundraising optionality.
The 3.0% commission structure to Leerink Partners is competitive for ATM offerings and reflects standard market terms, though the company bears all offering expenses and provides indemnification, typical for emerging growth companies seeking capital.
As an emerging growth company, Coya retains regulatory flexibility under scaled disclosure requirements, and the shelf registration on Form S-3 indicates the SEC previously qualified the company for efficient capital raising, suggesting prior compliance success.

Current Report Filed: 2026-01-30

Coya Therapeutics raised approximately $11.1 million in a private placement from key investors Dr. Reddy's Labs and Greenlight Capital.
The company plans to use the proceeds to tech transfer, scale up manufacturing, and accelerate programs for its lead candidate COYA 302.
Coya Therapeutics reiterated its cash runway guidance into the second half of 2027, extending past the projected topline readout for its ALSTARS trial.

Insider Trading Filed: 2026-01-26

Arun Swaminathan, the CEO of Coya Therapeutics, Inc. (COYA), has acquired 293,983 stock options with an exercise price of $4.73, vesting over the next 36 months.
The option grant is likely part of Swaminathan's compensation package and aligns his interests with shareholders through equity ownership.
The options will fully vest upon a change in control of the company, providing an incentive for Swaminathan to act in the best interests of shareholders during a potential acquisition or merger.

Insider Trading Filed: 2026-01-26

Insider Howard Berman, the Executive Chairman, acquired 15,257 stock options in Coya Therapeutics, Inc. on January 22, 2026 at an exercise price of $4.73.
The options will vest in monthly installments over the next 36 months, with full vesting upon a change in control of the company.
This insider purchase signals Berman's confidence in the company's prospects and long-term growth potential.

Insider Trading Filed: 2026-01-26

Fred Grossman, the Chief Medical Officer of Coya Therapeutics, Inc., has acquired 140,041 stock options with an exercise price of $4.73 and a 10-year expiration date.
The options will vest in monthly installments over the next 36 months, with accelerated vesting upon a change in control of the company.
This insider buying activity suggests that Grossman is confident in the company's future prospects and aligns his interests with those of shareholders.

Insider Trading Filed: 2026-01-26

David Snyder, the Chief Financial Officer of Coya Therapeutics, Inc. (COYA), has been granted 140,041 stock options with an exercise price of $4.73 and a vesting period of 36 months.
The stock options will become fully vested and exercisable upon a change in control of the company, indicating the potential importance of this transaction for Snyder and the company.
This filing suggests that Snyder is aligning his interests with the company's long-term success, as the options will only be valuable if the stock price increases over time.

Current Report Filed: 2026-01-20

Coya Therapeutics reported a strong cash balance of $46.8 million as of December 31, 2025, which provides a projected cash runway into the second half of 2027.
The company expects to report topline data readout from its ALSTARS Phase 2 trial in the first quarter of 2027, a key milestone for the company's pipeline.
As an emerging growth company, Coya Therapeutics may choose to take advantage of the extended transition period for complying with new or revised financial accounting standards.

Current Report Filed: 2026-01-08